²¹²Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro

References

• Allison J, Amako K, Apostolakis J, Arce P, Asai M, Aso T, Bagli E, Bagulya A, Banerjee S, Barrand G, et al. 2016. Recent developments in Geant4. Nucl Instruments Methods Phys Res Sect A Accel Spectrometers, Detect Assoc Equip [Internet]. 835:186–225. https://www.sciencedirect.com/science/article/pii/S0168900216306957.
   Web of Science ®Google Scholar
• Azure MT, Archer RD, Sastry KSR, Rao DV, Howell RW. 1994. Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters. Radiat Res. 140(2):276–283.
   Web of Science ®Google Scholar
• Baidoo KE, Milenic DE, Brechbiel MW. 2013. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol. 40(5):592–599.
   Web of Science ®Google Scholar
• Ballangrud ÅM, Yang W-H, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. 2004. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 10(13):4489–4497. http://clincancerres.aacrjournals.org/content/10/13/4489.abstract.
   PubMed Web of Science ®Google Scholar
• Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, et al. 2020. Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 61(1):80–88.
   PubMed Web of Science ®Google Scholar
• Barendsen GW, Beusker TL, Vergroesen AJ, Budke L. 1960. Effects of different radiations on human cells in tissue culture. II. Biological experiments. Radiat Res. 13:841–849.
   Web of Science ®Google Scholar
• Barendsen GW, Beusker TL. 1960. Effects of different ionizing radiations on human cells in tissue culture. I. Irradiation techniques and dosimetry. Radiat Res. 13:832–840.
   Web of Science ®Google Scholar
• Bellia SR, Feliciani G, Duca MD, Monti M, Turri V, Sarnelli A, Romeo A, Kelson I, Keisari Y, Popovtzer A, et al. 2019. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. J Contemp Brachytherapy. 11(5):449–457. https://pubmed.ncbi.nlm.nih.gov/31749854.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Dörr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DTL, Van Der Kogel AJ, Wambersie A, Whitmore G. 2012. Bioeffect modeling and equieffective dose concepts in radiation oncology-Terminology, quantities and units. Radiother Oncol. 105(2):266–268.
   Web of Science ®Google Scholar
• Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, Mairs RJ. 2006. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and auger electron–emitting radionuclides. J Nucl Med [Internet]. 47(6):1007 LP–1015. http://jnm.snmjournals.org/content/47/6/1007.abstract.
   Google Scholar
• Delpassand E, Tworowska I, Shanoon F, Nunez R, Flores L, II, Muzammil A, Stallons T, Saidi A, Torgue J. 2019. First clinical experience using targeted alpha-emitter therapy with < sup > 212</sup > Pb-DOTAMTATE (AlphaMedix < sup > TM</sup>) in patients with SSTR(+) neuroendocrine tumors. J Nucl Med [Internet]. 60(supplement 1):559 LP–559. http://jnm.snmjournals.org/content/60/supplement_1/559.abstract.
   Google Scholar
• Denoël T, Pedrelli L, Pantaleo G, Prior JO. 2019. A robust method for assaying the immunoreactive fraction in nonequilibrium systems. Pharmaceuticals. 12(4):177.
   Web of Science ®Google Scholar
• Eccles LJ, O'Neill P, Lomax ME. 2011. Delayed repair of radiation induced clustered DNA damage: friend or foe? Mutat Res. 711(1-2):134–141. https://pubmed.ncbi.nlm.nih.gov/21130102.
   PubMed Web of Science ®Google Scholar
• Elgqvist J, Frost S, Pouget J-P, Albertsson P. 2014. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 3:324. https://pubmed.ncbi.nlm.nih.gov/24459634.
   PubMedGoogle Scholar
• Feinendegen LE, McClure JJ. 1997. Alpha-emitters for medical therapy - Workshop of the United States Department of Energy. Denver, Colorado, May 30-31, 1996. In: Radiat Res. [place unknown].
   Google Scholar
• Freedman GM, White JR, Arthur DW, Allen Li X, Vicini FA. 2013. Accelerated fractionation with a concurrent boost for early stage breast cancer. Radiother Oncol. 106(1):15–20.
   PubMed Web of Science ®Google Scholar
• Group ST, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (London, England) [Internet]. 371(9618):1098–1107. https://pubmed.ncbi.nlm.nih.gov/18355913.
   PubMed Web of Science ®Google Scholar
• Gustafsson-Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. 2017. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Res. 7(1):38–45.
   PubMed Web of Science ®Google Scholar
• Hobbs RF, Howell RW, Song H, Baechler S, Sgouros G. 2014. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy. Radiat Res. 181(1):90–98.
   PubMed Web of Science ®Google Scholar
• Howell RW, Azure MT, Narra VR, Rao DV. 1994. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res. 137(3):352–360.
   Web of Science ®Google Scholar
• Karimian A, Ji NT, Song H, Sgouros G. 2020. Mathematical modeling of preclinical alpha-emitter radiopharmaceutical therapy. Cancer Res. 80(4):868–876.
   PubMed Web of Science ®Google Scholar
• Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. 2018. (212)Pb-Labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models. IJMS. 19(4):925. https://pubmed.ncbi.nlm.nih.gov/29561763.
   Google Scholar
• Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, et al. 2019. Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and nontargeted response to alpha and auger radioimmunotherapy. Clin Cancer Res. 25(15):4775–4790. http://clincancerres.aacrjournals.org/content/25/15/4775.abstract.
   PubMed Web of Science ®Google Scholar
• Maaland AF, Saidi A, Torgue J, Heyerdahl H, Rozgaja Stallons TA, Kolstad A, Dahle J. 2020. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS One. 15(3):e0230526.
   PubMed Web of Science ®Google Scholar
• Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, Morgan D, Fan J, Straughn JM. 2014. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 55(10):1636–1642. https://pubmed.ncbi.nlm.nih.gov/25157044.
   PubMed Web of Science ®Google Scholar
• Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. 2014a. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 29(1):12–17.
   PubMed Web of Science ®Google Scholar
• Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. 2014b. Pharmacokinetics and imaging of 212 Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 29(1):12–17.
   PubMed Web of Science ®Google Scholar
• Milenic DE, Molinolo AA, Solivella MS, Banaga E, Torgue J, Besnainou S, Brechbiel MW, Baidoo KE. 2015. Toxicological studies of 212Pb intravenously or intraperitoneally injected into mice for a phase 1 trial. Pharmaceuticals (Basel)). 8(3):416–434. https://pubmed.ncbi.nlm.nih.gov/26213947.
   PubMedGoogle Scholar
• Nikitaki Z, Nikolov V, Mavragani IV, Mladenov E, Mangelis A, Laskaratou DA, Fragkoulis GI, Hellweg CE, Martin OA, Emfietzoglou D, et al. 2016. Measurement of complex DNA damage induction and repair in human cellular systems after exposure to ionizing radiations of varying linear energy transfer (LET). Free Radic Res. 50(sup1):S64–S78..
   PubMed Web of Science ®Google Scholar
• Park SG, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. 2010. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 18(2):160–170.
   PubMed Web of Science ®Google Scholar
• Prise KM, O'Sullivan JM. 2009. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 9(5):351–360. https://pubmed.ncbi.nlm.nih.gov/19377507.
   PubMed Web of Science ®Google Scholar
• Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, Garrier J, Cogne M, Durand-Panteix S. 2020. 212Pb α-radioimmunotherapy targeting CD38 in multiple myeloma: a preclinical study. J Nucl Med. 61(7):1058–1065.
   PubMed Web of Science ®Google Scholar
• Reilly RT, Gottlieb MBC, Ercolini AM, Machiels JPH, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60(13):3569–3576.
   PubMed Web of Science ®Google Scholar
• Reilly RT, Machiels JPH, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. 2001. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61(3):880–883.
   Web of Science ®Google Scholar
• Rotmensch J, Atcher RW, Hines J, Grdina D, Schwartz JS, Toohill M, Herbst AL. 1989. The development of α-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. Am J Obstet Gynecol. 160(4):789–797.
   Web of Science ®Google Scholar
• Schneider NR, Lobaugh M, Tan Z, Sandwall P, Chen P, Glover SE, Cui L, Murry M, Dong Z, Torgue J, et al. 2013. Biodistribution of 212Pb conjugated trastuzumab in mice. In. J Radioanal Nucl Chem. 296(1):75–81.
   Web of Science ®Google Scholar
• Sgouros G, Bodei L, McDevitt MR, Nedrow JR. 2020. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 19(9):589–608.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G, SNM MIRD Committee, et al. 2010. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 51(2):311–328.https://pubmed.ncbi.nlm.nih.gov/20080889.
   PubMed Web of Science ®Google Scholar
• Song H, Shahverdi K, Huso DL, Wang Y, Fox JJ, Hobbs RF, Gimi B, Gabrielson KL, Pomper MG, Tsui BM, et al. 2008. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res. 14(19):6116–6124.
   PubMed Web of Science ®Google Scholar
• Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ. 2019. Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model. Mol Cancer Ther. 18(5):1012–1021.
   PubMed Web of Science ®Google Scholar
• Tamborino G, De Saint-Hubert M, Struelens L, Seoane DC, Ruigrok EAM, Aerts A, van Cappellen WA, de Jong M, Konijnenberg MW, Nonnekens J. 2020. Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. EJNMMI Phys. 7(1):8.
   PubMed Web of Science ®Google Scholar
• Thomas P, Tracy B, Ping T, Baweja A, Wickstrom M, Sidhu N, Hiebert L. 2007. Relative biological effectiveness (RBE) of alpha radiation in cultured porcine aortic endothelial cells. Int J Radiat Biol. 83(3):171–179.
   PubMed Web of Science ®Google Scholar
• Thorp-Greenwood FL, Coogan MP. 2011. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalt Trans. 40(23):6129–6143.
   Web of Science ®Google Scholar
• Vaziri B, Wu H, Dhawan AP, Du P, Howell RW, SNMMI MIRD Committee 2014. MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 55(9):1557–1564. http://jnm.snmjournals.org/content/55/9/1557.abstract.
   PubMed Web of Science ®Google Scholar
• Westrøm S, Generalov R, Bønsdorff TB, Larsen RH. 2017. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution. Nucl Med Biol. 51:1–9.
   PubMed Web of Science ®Google Scholar
• Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R. 2013. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One. 8(5):e64730.
   PubMed Web of Science ®Google Scholar
• Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME. 2019. Cellular and genetic determinants of the sensitivity of cancer to α-particle irradiation. Cancer Res. 79(21):5640–5651.
   PubMed Web of Science ®Google Scholar
• Yong K, Brechbiel M. 2015. Application of 212Pb for targeted α-particle therapy (TAT): pre-clinical and mechanistic understanding through to clinical translation. AIMS Med Sci. 2(3):228–245. https://pubmed.ncbi.nlm.nih.gov/26858987.
   PubMedGoogle Scholar
• Yu J, Lu R, Nedrow Jessie R, Sgouros G. 2020. Response of breast cancer carcinoma spheroids to combination therapy with radiation and DNA-PK inhibitor: Growth arrest without a change in α/β ratio. Int J Radiat Biol. 96(12):1534–1540.
   Google Scholar